Sign in

ARGX on Nasdaq

Argenx SE

Logo: Argenx SE, Public domain, via Wikimedia Commons5

Pharmaceutical company in Ghent, Belgium

Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.3 It employed 1,863 people in 2025.1 Its revenue was $4.2 billion in 2025.1 Its shares trade on Nasdaq under the symbol ARGX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$1.3BNet income, fiscal 20256
Apr 25, 2008Founded1

Compare with Innate Pharma SA, Valneva SE or Morphosys, or pick any stock.

  • TickerARGX on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersAmsterdam1
  • Websitewww.argenx.com
  • Legal formSocietas Europaea1
  • Listed onEuronext Brussels (ARGX), Nasdaq (ARGX)1
  • Incorporated inNetherlands7
  • Business addressIndustriepark Zwijnaarde 7, Building C B-9052, Zwijnaarde7
  • Filer categoryLarge accelerated filer7
  • LEI7245009C5FZE6G9ODQ714
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressLaarderhoogtweg 25, 1101EB Amsterdam, Netherlands4
  • Registered withThe Netherlands Chamber of Commerce, 244352144

See how the biggest companies compare on our leaderboards

Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2025

17.6%Return on equity6
679.0M EURFree cash flow6

Financial statements

Operating income91011121361.1B EUR in 2025
-1.0B EUR-500.0M EUR0500.0M EUR1.0B EUR1.5B EUR2018: -81.8M EUR-81.8M EUR20182019: -198.9M EUR-198.9M EUR2019+143%2020: -477.6M EUR-477.6M EUR2020+140%2021: -348.7M EUR-348.7M EUR2021−27%2022: -720.3M EUR-720.3M EUR2022+107%2023: -425.0M EUR-425.0M EUR2023−41%2024: -21.7M EUR-21.7M EUR2024−95%2025: 1.1B EUR1.1B EUR2025
Net income1411121361.3B EUR in 2025
-1.0B EUR01.0B EUR2.0B EUR2018: -66.6M EUR-66.6M EUR20182019: -163.0M EUR-163.0M EUR2019+145%2020: -608.5M EUR-608.5M EUR2020+273%2021: -408.3M EUR-408.3M EUR2021−33%2022: -709.6M EUR-709.6M EUR2022+74%2023: -295.1M EUR-295.1M EUR2023−58%2024: 833.0M EUR833.0M EUR20242025: 1.3B EUR1.3B EUR2025+55%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Product net sales$4.2B$2.2B$1.2B
Other operating income$96.7M$66.2M$77.8M
Total operating income$4.2B$2.3B$1.3B
Cost of sales-$450.7M-$227.3M-$117.8M
Research and development expenses-$1.4B-$983.4M-$859.5M
Selling, general and administrative expenses-$1.4B-$1.1B-$711.9M
Loss from investment in a joint venture-$12.4M-$7.6M-$4.4M
Total operating expenses-$3.2B-$2.3B-$1.7B
Operating profit/(loss)$1.1B-$21.7M-$425.0M
Financial income$163.1M$157.5M$107.4M
Financial expense-$4.1M-$2.5M-$906.0K
Exchange gains/(losses)$65.8M-$48.2M$14.1M
Profit/(Loss) for the year before taxes$1.3B$85.2M-$304.5M
Income tax benefit$13.4M$747.9M$9.4M
Profit/(Loss) for the year$1.3B$833.0M-$295.1M
Owners of the parent$1.3B$833.0M-$295.1M
Weighted average number of shares used for basic profit/(loss) per share (in shares)61.3M shares59.9M shares57.2M shares
Basic profit/(loss) per share (in USD per share)$21.08$13.92-$5.16
Weighted average number of shares used for diluted profit/(loss) per share (in shares)66.0M shares65.2M shares57.2M shares
Diluted profit/(loss) per share (in USD per share)$19.57$12.78-$5.16

Compare Argenx SE with another company

Corporate structure

Argenx SE sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Argenx SE

  • Argenx SE Amsterdam, Netherlands
    • ARGENX Subsidiary · 100% · Gent, Belgium

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Argenx SE reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$40.8M6 Dec 31, 2025$40.5M6 Dec 31, 2024+0.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.5B6 Dec 31, 2025$1.5B6 Dec 31, 2024+132.8%
Long-term investments$47.2M6 Dec 31, 2025$40.4M6 Dec 31, 2024+16.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$272.1M6 Dec 31, 2025$181.4M6 Dec 31, 2024+50.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$473.5M6 Dec 31, 2025$407.2M6 Dec 31, 2024+16.3%
Raw materials$335.5M6 Dec 31, 2025$337.8M6 Dec 31, 2024−0.7%

The story

In 2008, Argenx, based in Ghent, was founded by three scientists: Tim Van Hauwermeiren, a former executive at Ablynx, and two of his colleagues, Hans de Haard and Torsten Dreier. Their aim was to bring new drugs for the treatment of autoimmune diseases to the market. Through collaboration with researchers, including the scientist Sally Ward, they developed a new generation of medicines targeting Immunoglobulin G autoantibodies.

In order to finance research, development, applications for marketing authorization and the commercialization of its medicines, the company was listed in the United States on the Nasdaq and in Belgium on the Brussels Stock Exchange, where it was added to the BEL 20 in June 2018.

In 2021, the company received marketing authorization from the United States Food and Drug Administration for its first medicine, Vyvgart (active substance: efgartigimod alfa), for the treatment of myasthenia gravis.

In 2023, the company experienced two setbacks in attempts to broaden the indications for its flagship medicine Vyvgart: clinical studies for the treatment of immune thrombocytopenic purpura (ITP) and then pemphigus were inconclusive.

In April 2025, the US FDA approved a prefilled syringe version of the company's immune disorder drug Vyvgart.

In September 2025, Argenx was added to the Euro Stoxx 50 Index.

From Wikipedia’s article on Argenx, shared under CC BY-SA 4.0.8

Employees over time

  • 20251,8631

Former names

  • argenx N.VMar 1, 2017 to Apr 21, 20177

Timeline

  1. May 18, 2017Went public Listed on NASDAQ1
  2. Jul 10, 2014Went public Listed on Euronext Brussels1
  3. Apr 25, 2008Founded Founded1

Calendar

Coming up

  1. Oct 22, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $5.18 a share, on Oct 30, 2025.15

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

145 filings to the SEC since October 2021: 5 annual reports, 21 large holders, 119 other. The latest 20:

  1. Oct 8, 20266-K EDGAR
  2. Sep 29, 20266-K EDGAR
  3. Aug 27, 20266-K EDGAR
  4. Aug 27, 2026SC TO-T/A EDGAR
  5. Aug 19, 2026SC TO-T/A EDGAR
  6. Aug 17, 20266-K EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 6, 2026SC TO-T/A EDGAR
  9. Aug 6, 2026SC TO-T EDGAR
  10. Aug 3, 20266-K EDGAR
  11. Jul 28, 2026SC TO-C EDGAR
  12. Jul 27, 2026SC TO-C EDGAR
  13. Jul 27, 20266-K EDGAR
  14. Jul 23, 20266-K EDGAR
  15. Jun 23, 20266-K EDGAR
  16. Jun 3, 20266-K EDGAR
  17. May 11, 20266-K EDGAR
  18. May 7, 20266-K EDGAR
  19. May 6, 20266-K EDGAR
  20. May 6, 2026SCHEDULE 13G/A EDGAR

The 145 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC5,231,452$4.9B0.2%+240,418
Jupiter Topco LLC2,474,015$2.3B0.9%New
Capital World Investors2,199,770$2.0B0.2%−56,446
Artisan Partners Limited Partnership1,508,778$1.4B2.3%+40,796
Avoro Capital Advisors LLC1,000,000$927.8M8.3%No change
Wellington Management Group Llp930,548$863.3M0.1%−90,909
BlackRock, Inc.777,237$721.1M0.0%−31,100
Rtw Investments, LP709,446$658.2M5.6%No change
Morgan Stanley643,123$596.7M0.0%+82,412
Invesco Ltd.443,990$411.9M0.0%−150,707
Bank Of America Corp /de/400,234$371.3M0.0%+117
Alliancebernstein L.P.395,661$288.9M0.1%−26,643
Bellevue Group AG301,000$279.3M5.9%−12,000
Sands Capital Management, LLC298,599$277.0M1.0%−41,686
William Blair Investment Management, LLC264,617$245.5M0.7%−1,450
Sei Investments Co255,073$236.7M0.2%−31,893
Clearbridge Investments, LLC253,776$235.4M0.2%+22,420
Jennison Associates LLC226,200$209.9M0.1%−11,268
Franklin Resources Inc224,930$208.7M0.0%−8,563
Citadel Advisors LLC212,416$197.1M0.1%−6,710
Pictet Asset Management Holding SA198,282$183.8M0.2%+49,976
Two Sigma Investments, LP185,638$172.2M0.1%+76,517
Ameriprise Financial Inc181,464$168.4M0.0%−34,446
Goldman Sachs Group Inc177,846$165.0M0.0%−54,139
Legal & General Group Plc177,164$164.4M0.0%+26,314

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 30, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−5.8%Report
Jul 10, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000−36.4%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Argenx SE is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARARGENX SE2
  • CIK0001697862
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company20
  • Incorporated inNetherlands20
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business addressIndustriepark Zwijnaarde 7, Building C B-9052, Zwijnaarde, Ghent, Belgium2
  • Phone32 (9) 310 34 002
  • Shares outstanding61,883,306 shares as of Dec 31, 202520
  • AuditorEY Accountants B.V., Eindhoven, the Netherlands PCAOB ID 1396; it also attests to the company’s internal control over financial reporting20
  • On EDGAR sinceMar 1, 20172
  • Filings293 in all: 6-K (181), SC 13G/A (22), 424B5 (12), CORRESP (10), 20-F (9), UPLOAD (9), SC 13G (7), F-1/A (6)2
    All 25 form types

    SCHEDULE 13G/A (6), S-8 (4), SC TO-T/A (3), 424B4 (2), CERTNAS (2), CT ORDER (2), DRS (2), EFFECT (2), F-1 (2), F-1MEF (2), F-3ASR (2), FWP (2), SC TO-C (2), 8-A12B (1), DRS/A (1), DRSLTR (1), SC TO-T (1)

  • Latest filingsAnnual report (20-F) Mar 19, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one ordinary share with a nominal value of €0.10 per shareARGXNasdaq Global Select Market
Ordinary shares with a nominal value of €0.10 per share*ARGXNasdaq Global Select Market

From the cover page of the 20-F filed Mar 19, 2026 (Section 12(b) of the Exchange Act).20

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20